Yonatan Bitton-Faiwiszewski, MD
Interventional Cardiology · Englewood, CONPI 1558626796
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.7%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Medtronic at 40.8% of the total. Reporting peaked in 2024 at $17,533 and has fallen 75.3% since, to $4,338 in 2025.
Across 326 payments — averaging $109.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- Inari Medical, Inc.$4K
- Cagent Vascular Inc$3K
- Penumbra, Inc.$3K
- Angiodynamics, Inc.$2K
- Boston Scientific$2K
- plus $9K from 33 others
Across 97 payments — averaging $1601.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$49K
- Boston Scientific$47K
- M.a. Med Alliance S.A.$44K
- Abbott$16K
- Medalliance LLC$530
What the payments were for
- Consulting fees$2,6637%
- Speaking & faculty fees$5992%
- Travel & lodging$14,23140%
- Food & beverage$18,11051%
- Education$950%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 70 | $14,569 |
| Inari Medical, Inc. | 46 | $3,698 |
| Cagent Vascular Inc | 15 | $2,868 |
| Penumbra, Inc. | 12 | $2,783 |
| Angiodynamics, Inc. | 17 | $1,699 |
| Boston Scientific | 55 | $1,562 |
| Abbott | 17 | $1,284 |
| Philips North America LLC | 11 | $1,239 |
| Infraredx, Inc. | 1 | $1,000 |
| Cardiovascular Systems Inc. | 8 | $840 |
| Endologix LLC | 5 | $548 |
| Shockwave Medical, Inc | 3 | $484 |
| Cordis US CORP. | 4 | $462 |
| AstraZeneca | 7 | $312 |
| Inquis Medical, Inc. | 2 | $307 |
| Abiomed | 6 | $235 |
| Atricure, Inc. | 1 | $203 |
| Veryan Medical Incorporated | 2 | $174 |
| Biotronik Inc. | 2 | $172 |
| Actelion Pharmaceuticals US, Inc. | 4 | $168 |
| Edwards Lifesciences | 2 | $159 |
| E.r. Squibb & Sons, L.L.C. | 6 | $154 |
| Amgen | 7 | $147 |
| Avantec Vascular Corporation | 1 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $90 |
| Chiesi USA, Inc. | 4 | $67 |
| Pfizer | 2 | $47 |
| Cvrx, Inc. | 2 | $41 |
| Boehringer Ingelheim | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 1 | $31 |
| W. L. Gore & Associates, Inc. | 1 | $29 |
| Cardinal Health 200 LLC | 1 | $23 |
| Cleerly, Inc. | 1 | $23 |
| Mimedx Group, Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $20 |
| Novartis | 1 | $20 |
| Heartflow, Inc. | 1 | $19 |
| Stryker | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IN.PACT Admiral$7,236
- FLOWTRIEVER CATHETER, S$2,664
- CT THROMBECTOMY SYSTEM KIT$2,664
- Indigo System$2,376
- Serrantor$2,200
- ENDURANT IIS$1,391
- Valiant Captivia$1,165
- Auryon Laser System 100-120 Vac$1,021
- Abre$977
- HawkOne$813
- (9520) IGT Devices Undivided$600
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$441
- COREVALVE EVOLUT R$387
- ESPRIT$373
- Diamondback Coronary$368
- AlphaVac$346
- Coronary Orbital Atherectomy System$340
- Alto Abdominal Stent Graft System$327
- Aventus$307
- SYMPLICITY G3$300
How this compares
$35,697 in reported general payments places this provider in the 80th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 421 | $380,671 |
| EntrestoSacubitril/Valsartan | 237 | $244,872 |
| XareltoRivaroxaban | 177 | $168,156 |
| FarxigaDapagliflozin Propanediol | 84 | $68,951 |
| JardianceEmpagliflozin | 50 | $37,714 |
| Repatha SureclickEvolocumab | 40 | $23,645 |
| Praluent PenAlirocumab | 20 | $17,063 |
| Repatha SyringeEvolocumab | 29 | $9,568 |
| BrilintaTicagrelor | 15 | $8,359 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 28 | $5,723 |
| Rosuvastatin Calcium | 369 | $5,570 |
| Metoprolol Succinate | 502 | $5,384 |
| Atorvastatin Calcium | 761 | $4,543 |
| ClopidogrelClopidogrel Bisulfate | 503 | $4,374 |
| Carvedilol | 832 | $3,917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $47 | $380,671421 claims |
| NovartisEntresto | $20 | $244,872237 claims |
| AstraZenecaFarxiga, Brilinta | $312 | $77,31099 claims |
| Boehringer IngelheimJardiance | $36 | $37,71450 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Englewood
- Ehrin ArmstrongEnglewood$718K
- Travis TagamiEnglewood$25K
- Regina LeeEnglewood$12K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Nima AghiliLakewood$220K
- Sridhar Sampath-KumarAurora$142K
- Matthew ZipseAurora$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.